Raptor Pharmaceutical (RPTP -6.5%) slips after it says that the FDA will need an extra three...

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

Raptor Pharmaceutical (RPTP -6.5%) slips after it says that the FDA will need an extra three months to review the company's Proscysbi drug candidate to treat nephropathic cystinosis, a genetic disease typically affecting young children and infants.